Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist

Motoyuki Iida, Ikuko Miyazaki, Ken Ichi Tanaka, Hideaki Kabuto, Emi Iwata-Ichikawa, Norio Ogawa

Research output: Contribution to journalArticle

193 Citations (Scopus)

Abstract

Recent information suggests that free radicals are closely involved in the pathogenesis and/or progression of Parkinson's disease (PD). High-dose levodopa therapy has been suggested to increase oxidative stress, thereby accelerating the progression of PD. Based on this viewpoint, free radical scavenging, antioxidant and neuroprotective agents which may prevent the progression of PD have recently attracted considerable attention. For example, ergot derivative dopamine (DA) agonists have been reported to scavenge free radicals in vitro and show a neuroprotective effect in vivo. Non-ergot DA agonists have also recently been used in the treatment of PD despite the lack of substantial evidence for any free radical scavenging activity or antioxidant activity. The present study was conducted to assess the in vitro free radical scavenging and antioxidant activities of ropinirole, a non-ergot DA agonist, as well as its glutathione (GSH), catalase and superoxide dismutase (SOD) activating effects and neuroprotective effect in vivo. Ropinirole scavenges free radicals and suppresses lipid peroxidation in vitro, but these activities are very weak, suggesting that the antioxidant effect of ropinirole observed in vitro may be a minor component of its neuroprotective effect in vivo. Administration of ropinirole for 7 days increased GSH, catalase and SOD activities in the striatum and protected striatal dopaminergic neurons against 6- hydroxydopamine (6-OHDA) in mice. Pre-treatment with sulpiride prevented ropinirole from enhancing striatal GSH, catalase and SOD activities and abolished the protection of dopaminergic neurons against 6-OHDA. Our findings indicate that activation of GSH, catalase and SOD mediated via DA D2 receptors may be the principal mechanism of neuroprotection by ropinirole.

Original languageEnglish
Pages (from-to)51-59
Number of pages9
JournalBrain Research
Volume838
Issue number1-2
DOIs
Publication statusPublished - Aug 14 1999

Fingerprint

Dopamine D2 Receptors
Dopamine Agonists
Neuroprotective Agents
Free Radicals
Antioxidants
Catalase
Superoxide Dismutase
Parkinson Disease
Oxidopamine
Corpus Striatum
Dopaminergic Neurons
Sulpiride
Levodopa
Lipid Peroxidation
Glutathione
ropinirole
Oxidative Stress
In Vitro Techniques

Keywords

  • Antioxidant
  • Catalase
  • Free radical
  • Glutathione (GSH)
  • Neuroprotection
  • PD
  • Superoxide dismutase (SOD)

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. / Iida, Motoyuki; Miyazaki, Ikuko; Tanaka, Ken Ichi; Kabuto, Hideaki; Iwata-Ichikawa, Emi; Ogawa, Norio.

In: Brain Research, Vol. 838, No. 1-2, 14.08.1999, p. 51-59.

Research output: Contribution to journalArticle

Iida, Motoyuki ; Miyazaki, Ikuko ; Tanaka, Ken Ichi ; Kabuto, Hideaki ; Iwata-Ichikawa, Emi ; Ogawa, Norio. / Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. In: Brain Research. 1999 ; Vol. 838, No. 1-2. pp. 51-59.
@article{cf965c73f0454625a138f6c846ab14fc,
title = "Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist",
abstract = "Recent information suggests that free radicals are closely involved in the pathogenesis and/or progression of Parkinson's disease (PD). High-dose levodopa therapy has been suggested to increase oxidative stress, thereby accelerating the progression of PD. Based on this viewpoint, free radical scavenging, antioxidant and neuroprotective agents which may prevent the progression of PD have recently attracted considerable attention. For example, ergot derivative dopamine (DA) agonists have been reported to scavenge free radicals in vitro and show a neuroprotective effect in vivo. Non-ergot DA agonists have also recently been used in the treatment of PD despite the lack of substantial evidence for any free radical scavenging activity or antioxidant activity. The present study was conducted to assess the in vitro free radical scavenging and antioxidant activities of ropinirole, a non-ergot DA agonist, as well as its glutathione (GSH), catalase and superoxide dismutase (SOD) activating effects and neuroprotective effect in vivo. Ropinirole scavenges free radicals and suppresses lipid peroxidation in vitro, but these activities are very weak, suggesting that the antioxidant effect of ropinirole observed in vitro may be a minor component of its neuroprotective effect in vivo. Administration of ropinirole for 7 days increased GSH, catalase and SOD activities in the striatum and protected striatal dopaminergic neurons against 6- hydroxydopamine (6-OHDA) in mice. Pre-treatment with sulpiride prevented ropinirole from enhancing striatal GSH, catalase and SOD activities and abolished the protection of dopaminergic neurons against 6-OHDA. Our findings indicate that activation of GSH, catalase and SOD mediated via DA D2 receptors may be the principal mechanism of neuroprotection by ropinirole.",
keywords = "Antioxidant, Catalase, Free radical, Glutathione (GSH), Neuroprotection, PD, Superoxide dismutase (SOD)",
author = "Motoyuki Iida and Ikuko Miyazaki and Tanaka, {Ken Ichi} and Hideaki Kabuto and Emi Iwata-Ichikawa and Norio Ogawa",
year = "1999",
month = "8",
day = "14",
doi = "10.1016/S0006-8993(99)01688-1",
language = "English",
volume = "838",
pages = "51--59",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist

AU - Iida, Motoyuki

AU - Miyazaki, Ikuko

AU - Tanaka, Ken Ichi

AU - Kabuto, Hideaki

AU - Iwata-Ichikawa, Emi

AU - Ogawa, Norio

PY - 1999/8/14

Y1 - 1999/8/14

N2 - Recent information suggests that free radicals are closely involved in the pathogenesis and/or progression of Parkinson's disease (PD). High-dose levodopa therapy has been suggested to increase oxidative stress, thereby accelerating the progression of PD. Based on this viewpoint, free radical scavenging, antioxidant and neuroprotective agents which may prevent the progression of PD have recently attracted considerable attention. For example, ergot derivative dopamine (DA) agonists have been reported to scavenge free radicals in vitro and show a neuroprotective effect in vivo. Non-ergot DA agonists have also recently been used in the treatment of PD despite the lack of substantial evidence for any free radical scavenging activity or antioxidant activity. The present study was conducted to assess the in vitro free radical scavenging and antioxidant activities of ropinirole, a non-ergot DA agonist, as well as its glutathione (GSH), catalase and superoxide dismutase (SOD) activating effects and neuroprotective effect in vivo. Ropinirole scavenges free radicals and suppresses lipid peroxidation in vitro, but these activities are very weak, suggesting that the antioxidant effect of ropinirole observed in vitro may be a minor component of its neuroprotective effect in vivo. Administration of ropinirole for 7 days increased GSH, catalase and SOD activities in the striatum and protected striatal dopaminergic neurons against 6- hydroxydopamine (6-OHDA) in mice. Pre-treatment with sulpiride prevented ropinirole from enhancing striatal GSH, catalase and SOD activities and abolished the protection of dopaminergic neurons against 6-OHDA. Our findings indicate that activation of GSH, catalase and SOD mediated via DA D2 receptors may be the principal mechanism of neuroprotection by ropinirole.

AB - Recent information suggests that free radicals are closely involved in the pathogenesis and/or progression of Parkinson's disease (PD). High-dose levodopa therapy has been suggested to increase oxidative stress, thereby accelerating the progression of PD. Based on this viewpoint, free radical scavenging, antioxidant and neuroprotective agents which may prevent the progression of PD have recently attracted considerable attention. For example, ergot derivative dopamine (DA) agonists have been reported to scavenge free radicals in vitro and show a neuroprotective effect in vivo. Non-ergot DA agonists have also recently been used in the treatment of PD despite the lack of substantial evidence for any free radical scavenging activity or antioxidant activity. The present study was conducted to assess the in vitro free radical scavenging and antioxidant activities of ropinirole, a non-ergot DA agonist, as well as its glutathione (GSH), catalase and superoxide dismutase (SOD) activating effects and neuroprotective effect in vivo. Ropinirole scavenges free radicals and suppresses lipid peroxidation in vitro, but these activities are very weak, suggesting that the antioxidant effect of ropinirole observed in vitro may be a minor component of its neuroprotective effect in vivo. Administration of ropinirole for 7 days increased GSH, catalase and SOD activities in the striatum and protected striatal dopaminergic neurons against 6- hydroxydopamine (6-OHDA) in mice. Pre-treatment with sulpiride prevented ropinirole from enhancing striatal GSH, catalase and SOD activities and abolished the protection of dopaminergic neurons against 6-OHDA. Our findings indicate that activation of GSH, catalase and SOD mediated via DA D2 receptors may be the principal mechanism of neuroprotection by ropinirole.

KW - Antioxidant

KW - Catalase

KW - Free radical

KW - Glutathione (GSH)

KW - Neuroprotection

KW - PD

KW - Superoxide dismutase (SOD)

UR - http://www.scopus.com/inward/record.url?scp=0033554203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033554203&partnerID=8YFLogxK

U2 - 10.1016/S0006-8993(99)01688-1

DO - 10.1016/S0006-8993(99)01688-1

M3 - Article

C2 - 10446316

AN - SCOPUS:0033554203

VL - 838

SP - 51

EP - 59

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1-2

ER -